XAIR Board cuts director option strike to $1.95; terms unchanged
Rhea-AI Filing Summary
Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.
Positive
- None.
Negative
- None.
Insights
Director options repriced to $1.95; terms otherwise unchanged.
Beyond Air reduced the exercise price of certain director stock options to $1.95 per share, aligning with the prior trading close on November 3, 2025. The mechanism shown is a cancel-and-regrant (or administrative adjustment) reflected as dispositions at $10.80 and acquisitions at $1.95, with identical option counts per line.
Vesting continues per the original schedule under the 2013 Equity Incentive Plan, contingent on continued service. The filing lists specific entries of 187 options per item, indicating the scope of adjustments for those grants.
Actual impact depends on future exercises and holder decisions. Subsequent filings may provide additional context on aggregate option totals affected across all grants.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (Right to buy) | 187 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 187 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 187 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 187 | $0.00 | -- |
Footnotes (1)
- On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.